Company profile
RECURSION PHARMACEUTICALS, INC.
NASDAQ:RXRXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| REC-2282 | phase2_3 | — | 1 | terminated |
| TAK-733 | phase1 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06678659 | phase1_2 | recruiting | 2024-11-21 | 2028-10-30 | Recursion Pharmaceuticals Inc. | A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer |
| NCT06005974 | phase2 | terminated | 2024-01-15 | 2025-02-24 | Recursion Pharmaceuticals Inc. | A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation |
| NCT06980116 | phase1 | recruiting | 2025-03-31 | 2028-06-01 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies |
| NCT07517198 | phase1 | recruiting | 2026-04-13 | 2029-03-01 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors |
| NCT05130866 | phase2_3 | terminated | 2022-06-20 | 2025-08-18 | Recursion Pharmaceuticals Inc. | Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas |
FDA applications (0)
No records yet.